Optimized Dosing of ICLUSIG (ponatinib) in newly diagnosed Ph+ ALL

PhALLCON TRIAL DATA

Optimized, response-based dosing with ICLUSIG + chemotherapy for adults with newly diagnosed Ph+ ALL1

A starting dose of ICLUSIG 30 mg can be reduced to 15 mg once a patient achieves a meaningful response.

See how optimized, response-based dosing with ICLUSIG may help patients with newly diagnosed Ph+ ALL

ShowHide Transcript

[00:00:00.120] For adult patients with newly diagnosed Ph+ ALL or patients facing resistant
[00:00:05.480] or intolerant CP-CML, there is a high probability of developing mutations
[00:00:10.560] in BCR::ABL1. Mutations can lead to resistance and are the primary cause of relapse
[00:00:16.160] in patients in newly diagnosed Ph+ ALL.
[00:00:19.840] Prescribing an effective first-line treatment is critical to achieving MRD-negative
[00:00:24.920] CR at the end of induction in CML.
[00:00:27.640] Early identification of resistant mutations, including T315I,
[00:00:32.400] one of the most frequently identified,
[00:00:34.680] is crucial to informing your patients' next line of treatment.
[00:00:38.440] ICLUSIG is the first and only FDA-approved TKI for adults with newly diagnosed
[00:00:44.160] Ph+ ALL in combination with chemotherapy,
[00:00:47.560] and is also approved for adult patients with CP-CML with the T315I mutation
[00:00:53.595] or with resistance or intolerance to at least two prior TKIs.
[00:00:58.148] ICLUSIG was designed to bind across the BCR::ABL1 mutation spectrum,
[00:01:03.068] including T315I. ICLUSIG was designed with response-based dosing to help physicians
[00:01:08.988] optimize treatment based on individual patient response.
[00:01:12.708] For newly diagnosed Ph+ ALL, follow response-based dosing in combination
[00:01:18.108] with chemotherapy. Start with 30 mg,
[00:01:21.108] reduce to 15 mg in patients who achieve negative CR at the end of induction,
[00:01:26.388] and maintain for up to 20 cycles until loss of response or unacceptable toxicity.
[00:01:32.108] For patients with CP-CML who are resistant or intolerant to at least two prior TKIs,
[00:01:37.748] follow response-based dosing. Start at 45 mg to establish efficacy and reduce
[00:01:43.508] to 15 mg upon achieving less than or equal to 1% BCR::ABL1.
[00:01:49.068] Maintain on 15 mg as long as response is maintained.
[00:01:52.988] ICLUSIG is supported by Takeda Oncology Here2Assist®,
[00:01:56.868] here to help your patients with coverage and access, financial assistance,
[00:02:00.988] and educational resources. To enroll your patients and access coverage tools,
[00:02:05.908] sample letters, and copay support, contact a Here2Assist® Case Manager.
[00:02:10.588] Start strong with ICLUSIG for patients with newly diagnosed Ph+ ALL.
[00:02:16.308] Early identification of resistance is crucial to helping resistant or intolerant CP-CML.

To manage tolerability, follow these three steps:

Start with 30 mg

""

Start at 30 mg to establish efficacy.

Reduce to 15 mg

""

To manage tolerability, dose can be reduced to 15 mg once daily for patients who achieve an MRD-negative CR at the end of induction.

Maintain on 15 mg

""

Continue ICLUSIG in combination with chemotherapy for up to 20 cycles until loss of response or unacceptable toxicity.*

*One cycle is 28 days.

1L=first-line; CR=complete remission; MRD=minimal residual disease; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia.
ICLUSIG (ponatinib) dosing instructions: one pill, once a day, with or without food.

View ICLUSIG efficacy data in PhALLCON Trial

View ICLUSIG safety profile in PhALLCON Trial

Ph+ ALL Patient Profiles

""

Ph+ ALL Dosing Guide

""

Ph+ ALL resources and support

""